29 results on '"Spolding, Briana"'
Search Results
2. Metergoline Shares Properties with Atypical Antipsychotic Drugs Identified by Gene Expression Signature Screen
- Author
-
Bortolasci, Chiara C, Jaehne, Emily J, Hernández, Damián, Spolding, Briana, Connor, Timothy, Panizzutti, Bruna, Dean, Olivia M, Crowley, Tamsyn M, Yung, Alison R, Gray, Laura, Kim, Jee Hyun, van den Buuse, Maarten, Berk, Michael, and Walder, Ken
- Published
- 2023
- Full Text
- View/download PDF
3. Common effects of bipolar disorder medications on expression quantitative trait loci genes
- Author
-
Truong, Trang TT., Bortolasci, Chiara C., Kidnapillai, Srisaiyini, Spolding, Briana, Panizzutti, Bruna, Liu, Zoe SJ., Watmuff, Brad, Kim, Jee Hyun, Dean, Olivia M., Richardson, Mark, Berk, Michael, and Walder, Ken
- Published
- 2022
- Full Text
- View/download PDF
4. Systemic inflammation and grey matter volume in schizophrenia and bipolar disorder: Moderation by childhood trauma severity
- Author
-
Quidé, Yann, Bortolasci, Chiara C., Spolding, Briana, Kidnapillai, Srisaiyini, Watkeys, Oliver J., Cohen-Woods, Sarah, Carr, Vaughan J., Berk, Michael, Walder, Ken, and Green, Melissa J.
- Published
- 2021
- Full Text
- View/download PDF
5. Use of a gene expression signature to identify trimetazidine for repurposing to treat bipolar depression.
- Author
-
Bortolasci, Chiara C., Kidnapillai, Srisaiyini, Spolding, Briana, Truong, Trang T. T., Connor, Timothy, Swinton, Courtney, Panizzutti, Bruna, Liu, Zoe S. J., Sanigorski, Andrew, Dean, Olivia M., Crowley, Tamsyn, Richardson, Mark, Bozaoglu, Kiymet, Vlahos, Katerina, Cowdery, Stephanie, Watmuff, Brad, Steyn, Stephan F., Wolmarans, De Wet, Engelbrecht, Barend J., and Perry, Christina
- Subjects
BIPOLAR disorder ,TRIMETAZIDINE ,INDUCED pluripotent stem cells ,GENE expression ,MONONUCLEAR leukocytes - Abstract
Objectives: The aim of this study was to repurpose a drug for the treatment of bipolar depression. Methods: A gene expression signature representing the overall transcriptomic effects of a cocktail of drugs widely prescribed to treat bipolar disorder was generated using human neuronal‐like (NT2‐N) cells. A compound library of 960 approved, off‐patent drugs were then screened to identify those drugs that affect transcription most similar to the effects of the bipolar depression drug cocktail. For mechanistic studies, peripheral blood mononuclear cells were obtained from a healthy subject and reprogrammed into induced pluripotent stem cells, which were then differentiated into co‐cultured neurons and astrocytes. Efficacy studies were conducted in two animal models of depressive‐like behaviours (Flinders Sensitive Line rats and social isolation with chronic restraint stress rats). Results: The screen identified trimetazidine as a potential drug for repurposing. Trimetazidine alters metabolic processes to increase ATP production, which is thought to be deficient in bipolar depression. We showed that trimetazidine increased mitochondrial respiration in cultured human neuronal‐like cells. Transcriptomic analysis in induced pluripotent stem cell‐derived neuron/astrocyte co‐cultures suggested additional mechanisms of action via the focal adhesion and MAPK signalling pathways. In two different rodent models of depressive‐like behaviours, trimetazidine exhibited antidepressant‐like activity with reduced anhedonia and reduced immobility in the forced swim test. Conclusion: Collectively our data support the repurposing of trimetazidine for the treatment of bipolar depression. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Metformin is Protective Against the Development of Mood Disorders.
- Author
-
Lake, Jacqueline, Bortolasci, Chiara C., Stuart, Amanda L., Pasco, Julie A., Kidnapillai, Srisaiyini, Spolding, Briana, Truong, Trang T. T., Panizzutti, Bruna, Liu, Zoe S. J., Dean, Olivia M., Crowley, Tamsyn, Richardson, Mark, Kim, Jee Hyun, Berk, Michael, Williams, Lana J., and Walder, Ken
- Subjects
AFFECTIVE disorders ,METFORMIN ,TYPE 2 diabetes ,PHARMACOGENOMICS ,DRUG repositioning ,RANDOMIZED controlled trials - Abstract
Introduction Mood disorders are a major cause of disability, and current treatment options are inadequate for reducing the burden on a global scale. The aim of this project was to identify drugs suitable for repurposing to treat mood disorders. Methods This mixed-method study utilized gene expression signature technology and pharmacoepidemiology to investigate drugs that may be suitable for repurposing to treat mood disorders. Results The transcriptional effects of a combination of drugs commonly used to treat mood disorders included regulation of the steroid and terpenoid backbone biosynthesis pathways, suggesting a mechanism involving cholesterol biosynthesis, and effects on the thyroid hormone signaling pathway. Connectivity Map analysis highlighted metformin, an FDA-approved treatment for type 2 diabetes, as a drug having global transcriptional effects similar to the mood disorder drug combination investigated. In a retrospective cohort study, we found evidence that metformin is protective against the onset of mood disorders. Discussion These results provide proof-of-principle of combining gene expression signature technology with pharmacoepidemiology to identify potential novel drugs for treating mood disorders. Importantly, metformin may have utility in the treatment of mood disorders, warranting future randomized controlled trials to test its efficacy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. A placebo-controlled, randomised pilot trial of N-acetylcysteine or placebo for cessation of tobacco smoking
- Author
-
Arancini, Lauren, Mohebbi, Mohammadreza, Berk, Michael, Dean, Olivia M., Bortolasci, Chiara C., Spolding, Briana, Zazula, Robson, and Dodd, Seetal
- Published
- 2021
- Full Text
- View/download PDF
8. Integrative Analyses of Transcriptomes to Explore Common Molecular Effects of Antipsychotic Drugs.
- Author
-
Truong, Trang T. T., Bortolasci, Chiara C., Kidnapillai, Srisaiyini, Spolding, Briana, Panizzutti, Bruna, Liu, Zoe S. J., Kim, Jee Hyun, Dean, Olivia M., Richardson, Mark F., Berk, Michael, and Walder, Ken
- Subjects
AMISULPRIDE ,ANTIPSYCHOTIC agents ,ARIPIPRAZOLE ,LOCUS (Genetics) ,GENE expression profiling ,TRANSCRIPTOMES ,PHARMACODYNAMICS - Abstract
There is little understanding of the underlying molecular mechanism(s) involved in the clinical efficacy of antipsychotics for schizophrenia. This study integrated schizophrenia-associated transcriptional perturbations with antipsychotic-induced gene expression profiles to detect potentially relevant therapeutic targets shared by multiple antipsychotics. Human neuronal-like cells (NT2-N) were treated for 24 h with one of the following antipsychotic drugs: amisulpride, aripiprazole, clozapine, risperidone, or vehicle controls. Drug-induced gene expression patterns were compared to schizophrenia-associated transcriptional data in post-mortem brain tissues. Genes regulated by each of four antipsychotic drugs in the reverse direction to schizophrenia were identified as potential therapeutic-relevant genes. A total of 886 genes were reversely expressed between at least one drug treatment (versus vehicle) and schizophrenia (versus healthy control), in which 218 genes were commonly regulated by all four antipsychotic drugs. The most enriched biological pathways include Wnt signaling and action potential regulation. The protein-protein interaction (PPI) networks found two main clusters having schizophrenia expression quantitative trait loci (eQTL) genes such as PDCD10, ANK2, and AKT3, suggesting further investigation on these genes as potential novel treatment targets. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Effects of Psychotropic Drugs on Ribosomal Genes and Protein Synthesis.
- Author
-
Liu, Zoe S. J., Truong, Trang T. T., Bortolasci, Chiara C., Spolding, Briana, Panizzutti, Bruna, Swinton, Courtney, Kim, Jee Hyun, Kidnapillai, Srisaiyini, Richardson, Mark F., Gray, Laura, Dean, Olivia M., McGee, Sean L., Berk, Michael, and Walder, Ken
- Subjects
PSYCHOPHARMACOLOGY ,PROTEIN synthesis ,AMISULPRIDE ,RIBOSOMAL proteins ,PSYCHIATRIC drugs ,RIBOSOMES ,NEUROBEHAVIORAL disorders - Abstract
Altered protein synthesis has been implicated in the pathophysiology of several neuropsychiatric disorders, particularly schizophrenia. Ribosomes are the machinery responsible for protein synthesis. However, there remains little information on whether current psychotropic drugs affect ribosomes and contribute to their therapeutic effects. We treated human neuronal-like (NT2-N) cells with amisulpride (10 µM), aripiprazole (0.1 µM), clozapine (10 µM), lamotrigine (50 µM), lithium (2.5 mM), quetiapine (50 µM), risperidone (0.1 µM), valproate (0.5 mM) or vehicle control for 24 h. Transcriptomic and gene set enrichment analysis (GSEA) identified that the ribosomal pathway was altered by these drugs. We found that three of the eight drugs tested significantly decreased ribosomal gene expression, whilst one increased it. Most changes were observed in the components of cytosolic ribosomes and not mitochondrial ribosomes. Protein synthesis assays revealed that aripiprazole, clozapine and lithium all decreased protein synthesis. Several currently prescribed psychotropic drugs seem to impact ribosomal gene expression and protein synthesis. This suggests the possibility of using protein synthesis inhibitors as novel therapeutic agents for neuropsychiatric disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. Co-Expression Networks Unveiled Long Non-Coding RNAs as Molecular Targets of Drugs Used to Treat Bipolar Disorder.
- Author
-
Truong, Trang TT., Bortolasci, Chiara C., Spolding, Briana, Panizzutti, Bruna, Liu, Zoe SJ., Kidnapillai, Srisaiyini, Richardson, Mark, Gray, Laura, Smith, Craig M., Dean, Olivia M., Kim, Jee Hyun, Berk, Michael, and Walder, Ken
- Subjects
LINCRNA ,DRUG target ,BIPOLAR disorder ,DRUG development ,DRUG utilization ,GENE regulatory networks ,BIOLOGICAL networks - Abstract
Long non-coding RNAs (lncRNAs) may play a role in psychiatric diseases including bipolar disorder (BD). We investigated mRNA-lncRNA co-expression patterns in neuronal-like cells treated with widely prescribed BD medications. The aim was to unveil insights into the complex mechanisms of BD medications and highlight potential targets for new drug development. Human neuronal-like (NT2-N) cells were treated with either lamotrigine, lithium, quetiapine, valproate or vehicle for 24 h. Genome-wide mRNA expression was quantified for weighted gene co-expression network analysis (WGCNA) to correlate the expression levels of mRNAs with lncRNAs. Functional enrichment analysis and hub lncRNA identification was conducted on key co-expressed modules associated with the drug response. We constructed lncRNA-mRNA co-expression networks and identified key modules underlying these treatments, as well as their enriched biological functions. Processes enriched in key modules included synaptic vesicle cycle, endoplasmic reticulum-related functions and neurodevelopment. Several lncRNAs such as GAS6-AS1 and MIR100HG were highlighted as driver genes of key modules. Our study demonstrates the key role of lncRNAs in the mechanism(s) of action of BD drugs. Several lncRNAs have been suggested as major regulators of medication effects and are worthy of further investigation as novel drug targets to treat BD. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Methazolamide Is a New Hepatic Insulin Sensitizer That Lowers Blood Glucose In Vivo
- Author
-
Konstantopoulos, Nicky, Molero, Juan C., McGee, Sean L., Spolding, Briana, Connor, Tim, de Vries, Melissa, Wanyonyi, Stephen, Fahey, Richard, Morrison, Shona, Swinton, Courtney, Jones, Sharon, Cooper, Adrian, Garcia-Guerra, Lucia, Foletta, Victoria C., Krippner, Guy, Andrikopoulos, Sofianos, and Walder, Ken R.
- Published
- 2012
- Full Text
- View/download PDF
12. Effects of psychoactive drugs on cellular bioenergetic pathways.
- Author
-
Bortolasci, Chiara C., Spolding, Briana, Kidnapillai, Srisaiyini, Richardson, Mark F., Vasilijevic, Nina, Martin, Sheree D., Gray, Laura J., McGee, Sean L., Berk, Michael, and Walder, Ken
- Subjects
- *
PSYCHIATRIC drugs , *KREBS cycle , *GENE expression , *PHARMACODYNAMICS , *DRUG utilization - Abstract
To investigate the actions of lithium, valproate, lamotrigine and quetiapine on bioenergetic pathways in cultured NT2-N neuronal-like cells and C8-B4 microglial cells. NT2-N and C8-B4 cells were cultured and treated with lithium (2.5 mM), valproate (0.5 mM), quetiapine (0.05 mM) or lamotrigine (0.05 mM) for 24 hours. Gene expression and the mitochondrial bioenergetic profile were measured in both cell lines. In NT2-N cells, valproate increased oxidative phosphorylation (OXPHOS) gene expression, mitochondrial uncoupling and maximal respiratory capacity, while quetiapine decreased OXPHOS gene expression and respiration linked to ATP turnover, as well as decreasing the expression of genes in the citric acid cycle. Lamotrigine decreased OXPHOS gene expression but had no effect on respiration, while lithium reduced the expression of genes in the citric acid cycle. In C8-B4 cells, valproate and lithium increased OXPHOS gene expression, and valproate increased basal respiratory rate and maximal and spare respiratory capacities. In contrast, quetiapine significantly reduced basal respiratory rate and maximal and spare respiratory capacities. Overall our data suggest that some drugs used to treat neuropsychiatric and affective disorders have actions on a range of cellular bioenergetic processes, which could impact their effects in patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. The use of a gene expression signature and connectivity map to repurpose drugs for bipolar disorder.
- Author
-
Kidnapillai, Srisaiyini, Bortolasci, Chiara C., Udawela, Madhara, Panizzutti, Bruna, Spolding, Briana, Connor, Timothy, Sanigorski, Andrew, Dean, Olivia M., Crowley, Tamsyn, Jamain, Stéphane, Gray, Laura, Scarr, Elizabeth, Leboyer, Marion, Dean, Brian, Berk, Michael, and Walder, Ken
- Subjects
GENE expression ,BIPOLAR disorder ,MIFEPRISTONE ,DRUGS ,NUCLEOTIDE sequencing ,ARIPIPRAZOLE ,CAMPTOTHECIN - Abstract
To create a gene expression signature (GES) to represent the biological effects of a combination of known drugs for bipolar disorder (BD) on cultured human neuronal cells (NT2-N) and rat brains, which also has evidence of differential expression in individuals with BD. To use the GES to identify new drugs for BD using Connectivity Map (CMap).Methods: NT2-N (n = 20) cells and rats (n = 8) were treated with a BD drug combination (lithium, valproate, quetiapine and lamotrigine) or vehicle for 24 and 6 h, respectively. Following next-generation sequencing, the differential expression of genes was assessed using edgeR in R. The derived GES was compared to differentially expressed genes in post-mortem brains of individuals with BD. The GES was then used in CMap analysis to identify similarly acting drugs.Results: A total of 88 genes showed evidence of differential expression in response to the drug combination in both models, and therefore comprised the GES. Six of these genes showed evidence of differential expression in post-mortem brains of individuals with BD. CMap analysis identified 10 compounds (camptothecin, chlorambucil, flupenthixol, valdecoxib, rescinnamine, GW-8510, cinnarizine, lomustine, mifepristone and nimesulide) acting similarly to the BD drug combination.Conclusions: This study shows that GES and CMap can be used as tools to repurpose drugs for BD. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
14. Drugs used to treat bipolar disorder act via microRNAs to regulate expression of genes involved in neurite outgrowth.
- Author
-
Kidnapillai, Srisaiyini, Wade, Ben, Bortolasci, Chiara C, Panizzutti, Bruna, Spolding, Briana, Connor, Timothy, Crowley, Tamsyn, Jamain, Stéphane, Gray, Laura, Leboyer, Marion, Berk, Michael, and Walder, Ken
- Subjects
BIPOLAR disorder ,NOGO protein ,SUBSTANCE-induced disorders ,PHARMACOLOGY ,NEURON development ,DRUG efficacy - Abstract
Background: The drugs commonly used to treat bipolar disorder have limited efficacy and drug discovery is hampered by the paucity of knowledge of the pathophysiology of this disease. This study aims to explore the role of microRNAs in bipolar disorder and understand the molecular mechanisms of action of commonly used bipolar disorder drugs.Methods: The transcriptional effects of bipolar disorder drug combination (lithium, valproate, lamotrigine and quetiapine) in cultured human neuronal cells were studied using next generation sequencing. Differential expression of genes (n=20) and microRNAs (n=6) was assessed and the differentially expressed microRNAs were confirmed with TaqMan MicroRNA Assays. The expression of the differentially expressed microRNAs were inhibited to determine bipolar disorder drug effects on their target genes (n=8). Independent samples t-test was used for normally distributed data and Kruskal-Wallis/Mann-Whitney U test was used for data not distributed normally. Significance levels were set at p<0.05.Results: We found that bipolar disorder drugs tended to increase the expression of miR-128 and miR-378 (p<0.05). Putative target genes of these microRNAs targeted pathways including those identified as "neuron projection development" and "axonogenesis". Many of the target genes are inhibitors of neurite outgrowth and neurogenesis and were downregulated following bipolar disorder drug combination treatment (all p<0.05). The bipolar disorder drug combination tended to decrease the expression of the target genes (NOVA1, GRIN3A, and VIM), however this effect could be reversed by the application of microRNA inhibitors.Conclusions: We conclude that at a transcriptional level, bipolar disorder drugs affect several genes in concert that would increase neurite outgrowth and neurogenesis and hence neural plasticity, and that this effect is mediated (at least in part) by modulation of the expression of these two key microRNAs. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
15. Association between childhood trauma exposure and pro-inflammatory cytokines in schizophrenia and bipolar-I disorder.
- Author
-
Quidé, Yann, Bortolasci, Chiara C., Spolding, Briana, Kidnapillai, Srisaiyini, Watkeys, Oliver J., Cohen-Woods, Sarah, Berk, Michael, Carr, Vaughan J., Walder, Ken, and Green, Melissa J.
- Subjects
DIAGNOSIS of schizophrenia ,SCHIZOPHRENIA risk factors ,DIAGNOSIS of bipolar disorder ,C-reactive protein ,CYTOKINES ,INTERLEUKINS ,BIPOLAR disorder ,QUESTIONNAIRES ,RISK assessment ,SEX crimes ,TUMOR necrosis factors ,ADVERSE childhood experiences ,DISEASE risk factors - Abstract
Background: Elevated levels of pro-inflammatory cytokines are consistently reported in schizophrenia (SZ) and bipolar-I disorder (BD), as well as among individuals who have been exposed to childhood trauma. However, higher levels of inflammatory markers in these disorders are yet to be investigated with respect to levels of exposure to different types of childhood trauma. Methods: Participants were 68 cases with a diagnosis of schizophrenia/schizoaffective disorder (SZ), 69 cases with a diagnosis of psychotic BD and 72 healthy controls (HC). Serum levels of interleukin 6 (IL-6), tumour necrosis factor- α (TNF- α) and C-reactive protein (CRP) were quantified, and childhood trauma exposure was assessed with the Childhood Trauma Questionnaire. Results: The SZ group had significantly higher levels of IL-6, TNF- α and CRP when compared with the HC group (all p < 0.05, d = 0.41–0.63), as well as higher levels of TNF- α when compared with the BD group (p = 0.014, d = 0.50); there were no differences between the BD and HC groups for any markers. Exposure to sexual abuse was positively associated (standardised β = 0.326, t = 2.459, p = 0.018) with levels of CRP in the SZ group, but there were no significant associations between any form of trauma exposure and cytokine levels in the HC or BD groups. Conclusions: These results contribute to the evidence for a chronic state of inflammation in SZ but not BD cases. Differential associations between trauma exposure and levels of pro-inflammatory cytokines across the diagnostic categories suggest that trauma may impact biological (stress and immune) systems differently in these patient groups. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
16. Drugs used in the treatment of bipolar disorder and their effects on cholesterol biosynthesis – A possible therapeutic mechanism.
- Author
-
Kidnapillai, Srisaiyini, Bortolasci, Chiara C., Panizzutti, Bruna, Spolding, Briana, Connor, Timothy, Bonifacio, Kamila, Sanigorski, Andrew, Dean, Olivia M., Crowley, Tamsyn, Jamain, Stéphane, Gray, Laura, Leboyer, Marion, Berk, Michael, and Walder, Ken
- Subjects
LAMOTRIGINE ,BIPOLAR disorder ,CHOLESTEROL ,BIOSYNTHESIS ,OXIDATIVE phosphorylation ,DRUG prescribing - Abstract
Objectives: To understand the therapeutic mechanisms of bipolar disorder (BD) drugs at molecular and cellular levels. Methods: Next generation sequencing was used to determine the transcriptional effects of a combination of four commonly prescribed BD drugs (lithium, valproate, lamotrigine and quetiapine) or vehicle (0.2% DMSO) in NT2-N (human neuronal) cells and rats. Differential expression of genes and pathway analysis were performed using edgeR in R and Gene Set Enrichment Analysis software respectively. Free cholesterol levels and neurite outgrowth were quantified in NT2-N cells following combination and individual BD drug treatments. Results: Pathway analysis showed up-regulation of many elements of the cholesterol biosynthesis pathway in NT2-N cells and oxidative phosphorylation in rat brains. Intracellular cholesterol transport genes were upregulated (NPC1, NPC2 and APOE), while the cholesterol efflux gene (ABCA1) was downregulated. BD drug combination tended to increase intracellular cholesterol levels and neurite outgrowth, but these effects were not seen for the drugs when used individually. Conclusions: These data suggest that BD drug combination is increasing cholesterol biosynthesis and the newly synthesised cholesterol is being utilised within the cells, possibly for synthesis of new membranes to facilitate neurite outgrowth. This mechanism possibly underpins clinical efficacy in individuals with BD treated with polypharmacy. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
17. Diet during Pregnancy is Implicated in the Regulation of Hypothalamic RNA Methylation and Risk of Obesity in Offspring.
- Author
-
Kaspi, Antony, Khurana, Ishant, Ziemann, Mark, Connor, Timothy, Spolding, Briana, Zimmet, Paul, Walder, Ken, and El‐Osta, Assam
- Published
- 2018
- Full Text
- View/download PDF
18. Mechanisms Underpinning the Polypharmacy Effects of Medications in Psychiatry.
- Author
-
Bortolasci, Chiara C, Spolding, Briana, Callaly, Edward, Martin, Sheree, Panizzutti, Bruna, Kidnapillai, Srisaiyini, Connor, Timothy, Hasebe, Kyoko, Mohebbi, Mohammadreza, and Dean, Olivia M
- Subjects
POLYPHARMACY ,PSYCHIATRY ,DRUG therapy ,COGNITIVE ability ,DRUG interactions - Abstract
Background Bipolar disorder is a mental health condition with progressive social and cognitive function disturbances. Most patients’ treatments are based on polypharmacy, but with no biological basis and little is known of the drugs’ interactions. The aim of this study was to analyze the effects of lithium, valproate, quetiapine, and lamotrigine, and the interactions between them, on markers of inflammation, bioenergetics, mitochondrial function, and oxidative stress in neuron-like cells and microglial cells. Methods Neuron-like cells and lipopolysaccharide-stimulated C8-B4 cells were treated with lithium (2.5 mM), valproate (0.5 mM), quetiapine (0.05 mM), and lamotrigine (0.05 mM) individually and in all possible combinations for 24 h. Twenty cytokines were measured in the media from lipopolysaccharide-stimulated C8-B4 cells. Metabolic flux analysis was used to measure bioenergetics, and real-time PCR was used to measure the expression of mitochondrial function genes in neuron-like cells. The production of superoxide in treated cells was also assessed. Results The results suggest major inhibitory effects on proinflammatory cytokine release as a therapeutic mechanism of these medications when used in combination. The various combinations of medications also caused overexpression of PGC1α and ATP5A1 in neuron-like cells. Quetiapine appears to have a proinflammatory effect in microglial cells, but this was reversed by the addition of lamotrigine independent of the drug combination. Conclusion Polypharmacy in bipolar disorder may have antiinflammatory effects on microglial cells as well as effects on mitochondrial biogenesis in neuronal cells. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
19. Adjunctive N-acetylcysteine in depression: exploration of interleukin-6, C-reactive protein and brain-derived neurotrophic factor.
- Author
-
Hasebe, Kyoko, Gray, Laura, Bortolasci, Chiara, Panizzutti, Bruna, Mohebbi, Mohammadreza, Kidnapillai, Srisaiyini, Spolding, Briana, Walder, Ken, Berk, Michael, Malhi, Gin, Dodd, Seetal, and Dean, Olivia M.
- Subjects
ACETYLCYSTEINE ,MENTAL depression ,INTERLEUKIN-6 ,C-reactive protein ,NEUROTROPHINS - Abstract
ObjectiveThis study aimed to explore effects of adjunctive N-acetylcysteine (NAC) treatment on inflammatory and neurogenesis markers in unipolar depression.MethodsWe embarked on a 12-week clinical trial of NAC (2000 mg/day compared with placebo) as an adjunctive treatment for unipolar depression. A follow-up visit was conducted 4 weeks following the completion of treatment. We collected serum samples at baseline and the end of the treatment phase (week 12) to determine changes in interleukin-6 (IL6), C-reactive protein (CRP) and brain-derived neurotrophic factor (BDNF) following NAC treatment.ResultsNAC treatment significantly improved depressive symptoms on the Montgomery–Asberg Depression Rating Scale (MADRS) over 16 weeks of the trial. Serum levels of IL6 were associated with reductions of MADRS scores independent of treatment response. However, we found no significant changes in IL6, CRP and BDNF levels following NAC treatment.ConclusionOverall, this suggests that our results failed to support the hypothesis that IL6, CRP and BDNF are directly involved in the therapeutic mechanism of NAC in depression. IL6 may be a useful marker for future exploration of treatment response. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
20. Prevalence of beak and feather disease virus in wild Platycercus elegans: comparison of three tissue types using a probe-based real-time qPCR test.
- Author
-
Eastwood, Justin R., Berg, Mathew L., Spolding, Briana, Buchanan, Katherine L., Bennett, Andrew T. D., Walder, Ken, and Cooper, Steven
- Subjects
BIRD diseases ,VIREMIA ,PLATYCERCUS elegans ,ANIMAL genetics research ,FEATHERS - Abstract
The detection of avian viruses in wild populations has considerable conservation implications. For DNA-based studies, feathers may be a convenient sample type for virus screening and are, therefore, an increasingly common technique. This is despite recent concerns about DNA quality, ethics, and a paucity of data comparing the reliability and sensitivity of feather sampling to other common sample types such as blood. Alternatively, skeletal muscle tissue may offer a convenient sample to collect from dead birds, which may reveal viraemia. Here, we describe a probe-based quantitative real-time PCR for the relative quantification of beak and feather disease virus (BFDV), a pathogen of serious conservation concern for parrots globally. We used this method to test for BFDV in wild crimson rosellas (Platycercus elegans), and compared three different sample types. We detected BFDV in samples from 29 out of 84 individuals (34.5%). However, feather samples provided discordant results concerning virus presence when compared with muscle tissue and blood, and estimates of viral load varied somewhat between different sample types. This study provides evidence for widespread infection of BFDV in wild crimson rosellas, but highlights the importance of sample type when generating and interpreting qualitative and quantitative avian virus data. Beak and feather disease virus (BFDV) is a serious threat to parrot populations globally. Here, we show that BFDV is a prevalent and widespread infection in wild populations of crimson rosellas (Platycercus elegans). In addition, we highlight the importance of sample type when conducting viral testing in wild birds. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
21. Non-referenced genome assembly from epigenomic short-read data.
- Author
-
Kaspi, Antony, Ziemann, Mark, Keating, Samuel T, Khurana, Ishant, Connor, Timothy, Spolding, Briana, Cooper, Adrian, Lazarus, Ross, Walder, Ken, Zimmet, Paul, and El-Osta, Assam
- Published
- 2014
- Full Text
- View/download PDF
22. Rapid Development of Non-Alcoholic Steatohepatitis in Psammomys obesus (Israeli Sand Rat).
- Author
-
Spolding, Briana, Connor, Timothy, Wittmer, Carrie, Abreu, Lelia L. F., Kaspi, Antony, Ziemann, Mark, Kaur, Gunveen, Cooper, Adrian, Morrison, Shona, Lee, Scott, Sinclair, Andrew, Gibert, Yann, Trevaskis, James L., Roth, Jonathon D., El-Osta, Assam, Standish, Richard, and Walder, Ken
- Subjects
- *
FATTY liver , *THERAPEUTICS , *PSAMMOMYS obesus , *LABORATORY rats , *METABOLIC disorders , *DIETARY supplements , *CHOLESTEROL - Abstract
Background and Aims: A major impediment to establishing new treatments for non-alcoholic steatohepatitis is the lack of suitable animal models that accurately mimic the biochemical and metabolic characteristics of the disease. The aim of this study was to explore a unique polygenic animal model of metabolic disease as a model of non-alcoholic steatohepatitis by determining the effects of 2% dietary cholesterol supplementation on metabolic and liver endpoints in Psammomys obesus (Israeli sand rat). Methods: P. obesus were provided ad libitum access to either a standard rodent diet (20% kcal/fat) or a standard rodent diet supplemented with 2% cholesterol (w/w) for 4 weeks. Histological sections of liver from animals on both diets were examined for key features of non-alcoholic steatohepatitis. The expression levels of key genes involved in hepatic lipid metabolism were measured by real-time PCR. Results: P. obesus fed a cholesterol-supplemented diet exhibited profound hepatomegaly and steatosis, and higher plasma transaminase levels. Histological analysis identified extensive steatosis, inflammation, hepatocyte injury and fibrosis. Hepatic gene expression profiling revealed decreased expression of genes involved in delivery and uptake of lipids, and fatty acid and triglyceride synthesis, and increased expression of genes involved in very low density lipoprotein cholesterol synthesis, triglyceride and cholesterol export. Conclusions: P. obesus rapidly develop non-alcoholic steatohepatitis when fed a cholesterol-supplemented diet that appears to be histologically and mechanistically similar to patients. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
23. Biological Mechanism(s) Underpinning the Association between Antipsychotic Drugs and Weight Gain.
- Author
-
Panizzutti, Bruna, Bortolasci, Chiara C., Spolding, Briana, Kidnapillai, Srisaiyini, Connor, Timothy, Richardson, Mark F., Truong, Trang T. T., Liu, Zoe S. J., Gray, Laura, Kim, Jee Hyun, Dean, Olivia M., Berk, Michael, and Walder, Ken
- Subjects
ANTIPSYCHOTIC agents ,WEIGHT gain ,DRUG metabolism ,LIPID metabolism ,PEOPLE with schizophrenia ,AGRANULOCYTOSIS - Abstract
Weight gain and consequent metabolic alterations are common side-effects of many antipsychotic drugs. Interestingly, several studies have suggested that improvement in symptoms and adverse metabolic effects are correlated. We used next generation sequencing data from NT-2 (human neuronal) cells treated with aripiprazole, amisulpride, risperidone, quetiapine, clozapine, or vehicle control, and compared with the Pillinger P-score (ranked from 0 to 1, indicating greater increase in weight gain and related metabolic parameters) to identify the genes most associated with the drugs' propensity to cause weight gain. The top 500 genes ranked for their correlation with the drugs' propensity to cause weight gain were subjected to pathway analysis using DAVID (NIH). We further investigated transcription factors (TFs) that are more likely to regulate the genes involved in these processes using the prediction tool of key TFs from TRRUST. The results suggest an enrichment for genes involved in lipid biosynthesis and metabolism, which are of interest for mechanisms underpinning weight-gain. The list of genes involved in the lipid pathways that correlated with weight gain was enriched for genes transcriptionally regulated by SREBF1 and SREBF2. Furthermore, quetiapine significantly increased the expression of SREBF1 and SREBF2 in NT-2 cells. Our results suggest that the effects of these antipsychotic drugs on lipid metabolism may be mediated, at least in part, via regulation of SREBF1/SREBF2 expression, with evidence of a direct effect of quetiapine on the expression of SREBF1/2. The effects of antipsychotic drugs on lipid metabolism may influence white matter structure (therapeutic effect) and the risk of weight gain, lipid disturbances, and, consequently, metabolic syndrome (adverse effects). Understanding the different molecular effects of these drugs could inform a personalized medicine approach in treating patients with schizophrenia. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
24. Transcriptional Modulation of the Hippo Signaling Pathway by Drugs Used to Treat Bipolar Disorder and Schizophrenia.
- Author
-
Panizzutti, Bruna, Bortolasci, Chiara C., Spolding, Briana, Kidnapillai, Srisaiyini, Connor, Timothy, Richardson, Mark F., Truong, Trang T. T., Liu, Zoe S. J., Morris, Gerwyn, Gray, Laura, Hyun Kim, Jee, Dean, Olivia M., Berk, Michael, and Walder, Ken
- Subjects
ARIPIPRAZOLE ,AMISULPRIDE ,DRUG utilization ,BIPOLAR disorder ,PSYCHIATRIC drugs ,SCHIZOPHRENIA ,ANTIPSYCHOTIC agents ,HIPPO signaling pathway - Abstract
Recent reports suggest a link between positive regulation of the Hippo pathway with bipolar disorder (BD), and the Hippo pathway is known to interact with multiple other signaling pathways previously associated with BD and other psychiatric disorders. In this study, neuronal-like NT2 cells were treated with amisulpride (10 µM), aripiprazole (0.1 µM), clozapine (10 µM), lamotrigine (50 µM), lithium (2.5 mM), quetiapine (50 µM), risperidone (0.1 µM), valproate (0.5 mM), or vehicle control for 24 h. Genome-wide mRNA expression was quantified and analyzed using gene set enrichment analysis (GSEA), with genes belonging to Hippo, Wnt, Notch, TGF- β, and Hedgehog retrieved from the KEGG database. Five of the eight drugs downregulated the genes of the Hippo pathway and modulated several genes involved in the interacting pathways. We speculate that the regulation of these genes, especially by aripiprazole, clozapine, and quetiapine, results in a reduction of MAPK and NFκB pro-inflammatory signaling through modulation of Hippo, Wnt, and TGF-β pathways. We also employed connectivity map analysis to identify compounds that act on these pathways in a similar manner to the known psychiatric drugs. Thirty-six compounds were identified. The presence of antidepressants and antipsychotics validates our approach and reveals possible new targets for drug repurposing. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
25. Transcriptional Effects of Psychoactive Drugs on Genes Involved in Neurogenesis.
- Author
-
Bortolasci, Chiara C., Spolding, Briana, Kidnapillai, Srisaiyini, Connor, Timothy, Truong, Trang T.T., Liu, Zoe S.J., Panizzutti, Bruna, Richardson, Mark F., Gray, Laura, Berk, Michael, Dean, Olivia M., and Walder, Ken
- Subjects
- *
PSYCHIATRIC drugs , *PHARMACOLOGY , *AMISULPRIDE , *DEVELOPMENTAL neurobiology , *GENE ontology , *MESSENGER RNA , *METABOLOMICS - Abstract
Although neurogenesis is affected in several psychiatric diseases, the effects and mechanisms of action of psychoactive drugs on neurogenesis remain unknown and/or controversial. This study aims to evaluate the effects of psychoactive drugs on the expression of genes involved in neurogenesis. Neuronal-like cells (NT2-N) were treated with amisulpride (10 µM), aripiprazole (0.1 µM), clozapine (10 µM), lamotrigine (50 µM), lithium (2.5 mM), quetiapine (50 µM), risperidone (0.1 µM), or valproate (0.5 mM) for 24 h. Genome wide mRNA expression was quantified and analysed using gene set enrichment analysis, with the neurogenesis gene set retrieved from the Gene Ontology database and the Mammalian Adult Neurogenesis Gene Ontology (MANGO) database. Transcription factors that are more likely to regulate these genes were investigated to better understand the biological processes driving neurogenesis. Targeted metabolomics were performed using gas chromatography-mass spectrometry. Six of the eight drugs decreased the expression of genes involved in neurogenesis in both databases. This suggests that acute treatment with these psychoactive drugs negatively regulates the expression of genes involved in neurogenesis in vitro. SOX2 and three of its target genes (CCND1, BMP4, and DKK1) were also decreased after treatment with quetiapine. This can, at least in part, explain the mechanisms by which these drugs decrease neurogenesis at a transcriptional level in vitro. These results were supported by the finding of increased metabolite markers of mature neurons following treatment with most of the drugs tested, suggesting increased proportions of mature relative to immature neurons consistent with reduced neurogenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
26. Front cover: Diet during Pregnancy is Implicated in the Regulation of Hypothalamic RNA Methylation and Risk of Obesity in Offspring.
- Author
-
Kaspi, Antony, Khurana, Ishant, Ziemann, Mark, Connor, Timothy, Spolding, Briana, Zimmet, Paul, Walder, Ken, and El‐Osta, Assam
- Published
- 2018
- Full Text
- View/download PDF
27. The potential of baicalin to enhance neuroprotection and mitochondrial function in a human neuronal cell model.
- Author
-
Liu ZSJ, Truong TTT, Bortolasci CC, Spolding B, Panizzutti B, Swinton C, Kim JH, Hernández D, Kidnapillai S, Gray L, Berk M, Dean OM, and Walder K
- Abstract
Baicalin is a flavone glycoside derived from flowering plants belonging to the Scutellaria genus. Previous studies have reported baicalin's anti-inflammatory and neuroprotective properties in rodent models, indicating the potential of baicalin in neuropsychiatric disorders where alterations in numerous processes are observed. However, the extent of baicalin's therapeutic effects remains undetermined in a human cell model, more specifically, neuronal cells to mimic the brain environment in vitro. As a proof of concept, we treated C8-B4 cells (murine cell model) with three different doses of baicalin (0.1, 1 and 5 μM) and vehicle control (DMSO) for 24 h after liposaccharide-induced inflammation and measured the levels of TNF-α in the medium by ELISA. NT2-N cells (human neuronal-like cell model) underwent identical baicalin treatment, followed by RNA extraction, genome-wide mRNA expression profiles and gene set enrichment analysis (GSEA). We also performed neurite outgrowth assays and mitochondrial flux bioanalysis (Seahorse) in NT2-N cells. We found that in C8-B4 cells, baicalin at ≥ 1 μM exhibited anti-inflammatory effects, lowering TNF-α levels in the cell culture media. In NT2-N cells, baicalin positively affected neurite outgrowth and transcriptionally up-regulated genes in the tricarboxylic acid cycle and the glycolysis pathway. Similarly, Seahorse analysis showed increased oxygen consumption rate in baicalin-treated NT2-N cells, an indicator of enhanced mitochondrial function. Together, our findings have confirmed the neuroprotective and mitochondria enhancing effects of baicalin in human-neuronal like cells. Given the increased prominence of mitochondrial mechanisms in diverse neuropsychiatric disorders and the paucity of mitochondrial therapeutics, this suggests the potential therapeutic application of baicalin in human neuropsychiatric disorders where these processes are altered., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
28. Genetic variation associated with hypersensitivity to mercury.
- Author
-
Austin DW, Spolding B, Gondalia S, Shandley K, Palombo EA, Knowles S, and Walder K
- Abstract
Objectives: Very little is known about mechanisms of idiosyncratic sensitivity to the damaging effects of mercury (Hg); however, there is likely a genetic component. The aim of the present study was to search for genetic variation in genes thought to be involved in Hg metabolism and transport in a group of individuals identified as having elevated Hg sensitivity compared to a normal control group., Materials and Methods: Survivors of pink disease (PD; infantile acrodynia) are a population of clinically identifiable individuals who are Hg sensitive. In the present study, single nucleotide polymorphisms in genes thought to be involved in Hg transport and metabolism were compared across two groups: (i) PD survivors (n = 25); and (ii) age- and sex-matched healthy controls (n = 25)., Results: Analyses revealed significant differences between groups in genotype frequencies for rs662 in the gene encoding paraoxanase 1 (PON1) and rs1801131 in the gene encoding methylenetetrahydrofolate reductase (MTHFR)., Conclusions: We have identified two genetic polymorphisms associated with increased sensitivity to Hg. Genetic variation in MTHFR and PON1 significantly differentiated a group formerly diagnosed with PD (a condition of Hg hypersensitivity) with age- and gender-matched healthy controls.
- Published
- 2014
- Full Text
- View/download PDF
29. Rapid development of non-alcoholic steatohepatitis in Psammomys obesus (Israeli sand rat).
- Author
-
Spolding B, Connor T, Wittmer C, Abreu LL, Kaspi A, Ziemann M, Kaur G, Cooper A, Morrison S, Lee S, Sinclair A, Gibert Y, Trevaskis JL, Roth JD, El-Osta A, Standish R, and Walder K
- Subjects
- Animals, Cholesterol, Dietary administration & dosage, Cholesterol, Dietary metabolism, Fatty Liver pathology, Gene Expression Profiling, Lipid Metabolism, Liver metabolism, Liver pathology, Male, Mice, Non-alcoholic Fatty Liver Disease, Disease Models, Animal, Fatty Liver etiology, Gerbillinae
- Abstract
Background and Aims: A major impediment to establishing new treatments for non-alcoholic steatohepatitis is the lack of suitable animal models that accurately mimic the biochemical and metabolic characteristics of the disease. The aim of this study was to explore a unique polygenic animal model of metabolic disease as a model of non-alcoholic steatohepatitis by determining the effects of 2% dietary cholesterol supplementation on metabolic and liver endpoints in Psammomys obesus (Israeli sand rat)., Methods: P. obesus were provided ad libitum access to either a standard rodent diet (20% kcal/fat) or a standard rodent diet supplemented with 2% cholesterol (w/w) for 4 weeks. Histological sections of liver from animals on both diets were examined for key features of non-alcoholic steatohepatitis. The expression levels of key genes involved in hepatic lipid metabolism were measured by real-time PCR., Results: P. obesus fed a cholesterol-supplemented diet exhibited profound hepatomegaly and steatosis, and higher plasma transaminase levels. Histological analysis identified extensive steatosis, inflammation, hepatocyte injury and fibrosis. Hepatic gene expression profiling revealed decreased expression of genes involved in delivery and uptake of lipids, and fatty acid and triglyceride synthesis, and increased expression of genes involved in very low density lipoprotein cholesterol synthesis, triglyceride and cholesterol export., Conclusions: P. obesus rapidly develop non-alcoholic steatohepatitis when fed a cholesterol-supplemented diet that appears to be histologically and mechanistically similar to patients.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.